Investor Presentation H1 2023

41 Investor presentation First six months of 2023 B-cell function Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise OAD GLP-1 Insulin Distribution of estimated prescriptions¹ and value across treatment classes 3% 11% 50% 21% 3% 13% 36% 13% 0.5% 5% 26% 19% Time Estimated Prescriptions Insulin SGLT-2i ■GLP-1 Inj. DPP-4i Value Oral GLP-1 Trad. OAD 1The estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions. Note: Other OADs cover: metformin, sulfonylurea, thiazolidinediones. OAD: Oral anti-diabetic Source: MIDAS; patient and value figures based on IQVIA MAT, May 2023 Novo NordiskⓇ

View entire presentation